OR WAIT null SECS
April 05, 2012
Ranbaxy Laboratories announced that beginning in March 2012, the first shipments of atorvastatin, the generic version of Pfizer's Lipitor, had been sent to US markets from its new Mohali manufacturing facility located in Punjab, India.
On Mar. 29, 2012, the Generic Pharmaceutical Association reiterated its call for Congress to move forward with user-fee proposals for generic drugs and biosimilar products.
March 15, 2012
AstraZeneca Files Suit Against FDA; Pfizer, Biocon Terminate Biosimilar Alliance; and More.
March 08, 2012
BASi Restructures; Celerion, Ricerca Biosciences Form Biosimilars Alliance; and More.
The Bulk Pharmaceuticals Task Force, an affiliate of the Society of Chemical Manufacturers and Affiliates (SOCMA), issued its support for the introduction of a House bill, the Generic Drug and Biosimilar User Fee Act (HR 3988), which SOCMA says will help to achieve parity between foreign and domestic firms.
March 02, 2012
SOCMA's Bulk Pharmaceuticals Task Force outlines key goals and challenges for user-fee legislation.
Has the long-awaited guidance answered all of the industry's questions?
March 01, 2012
The pharma industry has reached the long-dreaded patent cliff, but for copycat products, business is booming.
JHS Secures Four Sterile Parenteral Products Manufacturing Contracts; Samsung Biologics, Biogen Idec Establish Biosimilars Joint Venture; and More.
February 23, 2012
Pfizer has signed an agreement with the Chinese biopharmaceutical company Zhejiang Hisun Pharmaceuticals with the objective of establishing a $545-million joint venture to develop and commercialize branded generic medicines in both China and the global market.